Immune-targeted therapies break the cancer immune tolerance, restoring T-cell recognition against tumor cells and restraining the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1)/ligand 1 (PD-L1) pathways. This evidence concerns the gene CTLA4 and neoplasm.